Journal of Cancer Prevention

Korean Society of Cancer Prevention (대한암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-growth Effects of Imatinib and GNF5 via Regulation of Skp2 in Human Hepatocellular Carcinoma Cells

  • Kim, Sung Hyun (China-US (Henan) Hormel Cancer Institute) ;
  • Kim, Myoung-Ok (Department of Animal Science, College of Ecology and Environment Science, Kyungpook National University) ;
  • Kim, Ki-Rim (Department of Dental Hygiene, College of Science and Technology, Kyungpook National University)
  • Received : 2018.09.11
  • Accepted : 2018.09.27
  • Published : 2018.12.30
⟨ Previous Next ⟩

Abstract

Background: Human hepatocellular carcinoma (HCC) is a common liver tumor and the main cause of cancer-related death. Tyrosine kinase inhibitors, such as imatinib and GNF5 which were developed to treat chronic myelogenous leukemia, regulate the progression of various cancers. The aim of this study was to confirm the anti-tumor activity of tyrosine kinase inhibitors through regulation of S-phase kinase-associated protein 2 (Skp2), an important oncogenic factor in various cancer cells, in human hepatocarcinoma SK-HEP1 cells. Methods: Cell viability and colony formation assays were conducted to evaluate the effects of imatinib, GNF5 and GNF2 on the growth of SK-HEP1 cells. Using immunoblot analysis, we assessed change of the activation of caspases, PARP, Akt, mitogen-activated protein kinases, and Skp2/p27/p21 pathway by imatinib and GNF5 in SK-HEP1 cells. Using sh-Skp2 HCC cells, the role of Skp2 in the effects of imatinib and GNF5 was evaluated. Results: Imatinib and GNF5 significantly inhibited the growth of SK-HEP1 cells. Treatment of imatinib and GNF5 decreased Skp2 expression and Akt phosphorylation, and increased the expression of p27, p21, and active-caspases in SK-HEP1 cells. In sh-Skp2 HCC cells, cell growth and the expression of Skp2 were inhibited by more than in the mock group treated with imatinib and GNF5. Conclusions: These results suggest that the anti-growth activity of tyrosine kinase inhibitors may be associated with the regulation of p27/p21 and caspases through Skp2 blockage in HCC cells.

Keywords

References

  1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  2. Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002;35:S109-14. https://doi.org/10.1097/00004836-200211002-00007
  3. Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol 2017;9:907-20. https://doi.org/10.4254/wjh.v9.i21.907
  4. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008;8:438-49. https://doi.org/10.1038/nrc2396
  5. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000;19:2069-81. https://doi.org/10.1093/emboj/19.9.2069
  6. Calvisi DF, Ladu S, Pinna F, Frau M, Tomasi ML, Sini M, et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 2009;137:1816-26.e1-10. https://doi.org/10.1053/j.gastro.2009.08.005
  7. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53. https://doi.org/10.1182/blood-2004-08-3097
  8. Salesse S, Verfaillie CM. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 2002;21:8547-59. https://doi.org/10.1038/sj.onc.1206082
  9. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2:95-102. https://doi.org/10.1038/nchembio760
  10. Ramadori G, Fuzesi L, Grabbe E, Pieler T, Armbrust T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs 2004;15:405-9. https://doi.org/10.1097/00001813-200404000-00014
  11. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008;10:e19. https://doi.org/10.1017/S1462399408000744
  12. Tsatsanis C, Spandidos DA. The role of oncogenic kinases in human cancer (Review). Int J Mol Med 2000;5:583-90.
  13. Paul MK, Mukhopadhyay AK. Tyrosine kinase: role and significance in cancer. Int J Med Sci 2004;1:101-15.
  14. Hassan AQ, Sharma SV, Warmuth M. Allosteric inhibition of BCR-ABL. Cell Cycle 2010;9:3710-4.
  15. Keshavarz-Pakseresht B, Shandiz SA, Baghbani-Arani F. Imatinib induces up-regulation of NM23, a metastasis suppressor gene, in human Hepatocarcinoma (HepG2) cell line. Gastroenterol Hepatol Bed Bench 2017;10:29-33.
  16. Mitupatum T, Aree K, Kittisenachai S, Roytrakul S, Puthong S, Kangsadalampai S, et al. Hep88 mAb-mediated paraptosis-like apoptosis in HepG2 cells via downstream upregulation and activation of caspase-3, caspase-8 and caspase-9. Asian Pac J Cancer Prev 2015;16:1771-9. https://doi.org/10.7314/APJCP.2015.16.5.1771
  17. Ramirez-Tagle R, Escobar CA, Romero V, Montorfano I, Armisen R, Borgna V, et al. Chalcone-induced apoptosis through caspase-dependent intrinsic pathways in human hepatocellular carcinoma cells. Int J Mol Sci 2016;17:260. https://doi.org/10.3390/ijms17020260
  18. Wei Z, Jiang X, Qiao H, Zhai B, Zhang L, Zhang Q, et al. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal 2013;25:931-8. https://doi.org/10.1016/j.cellsig.2013.01.011
  19. Ohkoshi S, Yano M, Matsuda Y. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol 2015;21:12150-6. https://doi.org/10.3748/wjg.v21.i42.12150
  20. Auld CA, Caccia CD, Morrison RF. Hormonal induction of adipogenesis induces Skp2 expression through PI3K and MAPK pathways. J Cell Biochem 2007;100:204-16. https://doi.org/10.1002/jcb.21063
  21. Bu W, Luo T. miR-1297 Promotes cell proliferation of non-small cell lung cancer cells: involving in PTEN/Akt/Skp2 signaling pathway. DNA Cell Biol 2017;36:976-82. https://doi.org/10.1089/dna.2017.3886
  22. Liu X, Wang H, Ma J, Xu J, Sheng C, Yang S, et al. The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K/Akt pathway and cell proliferation. Med Oncol 2013;30:735. https://doi.org/10.1007/s12032-013-0735-0
  23. Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA, et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005;65:3264-72. https://doi.org/10.1158/0008-5472.CAN-04-1357